KPV Peptide
Inflammation Response
KPV (Lysine-Proline-Valine) is a potent anti-inflammatory tripeptide derived from alpha-melanocyte-stimulating hormone. Transcriptomics allows clinicians to track the inactivation of inflammatory transcription factors and the upregulation of barrier protective mucosal genes.
Tracked Physiological Dimensions
On the Advanced Transcriptomics Dashboard, KPV peptide activity is mapped primarily to the body's inflammatory signaling index.
Deactivating the Inflammatory Cascade
KPV acts intracellularly to suppress inflammatory signaling pathways, particularly by interacting directly with the cell nucleus to prevent NF-κB nuclear translocation. This suppresses downstream activation of multiple cytokines responsible for gut barrier decay and joint discomfort.
By monitoring active transcripts, clinicians can track systemic chronic inflammation resolution. Measuring mucosal genes like MUC2 provides proof of local barrier reinforcement in irritable bowel conditions, giving a definitive readout of peptide efficacy.
Key Target Genes
Interleukin 6 & Tumor Necrosis Factor Pro-inflammatory Cytokines
Key inflammatory cytokines; KPV suppresses their transcription to resolve tissue inflammation.
Interleukin 10 Anti-inflammatory Cytokines
Upregulated by KPV to promote immune tolerance and restore physiological homeostasis.
Nuclear Factor Kappa B Subunit 1 Inflammatory Transcription Factor
Primary mediator of the inflammatory cascade; actively down-regulated by KPV.
Mucin 2 Mucosal Barrier Integrity
Main structural component of the intestinal mucosal barrier; upregulated by KPV to support gut lining integrity.
Expected mRNA Expression Timeline
A typical timeline showing how active gene expression signals evolve during a KPV therapy cycle.
Acute Suppression
Downregulation of NF-κB and rapid decrease in IL-6 and TNF-α cytokine transcripts.
Barrier Reinforcement
Peak expression of mucosal protection genes (MUC2) and anti-inflammatory cytokines (IL-10).
Systemic Remission
Long-term stabilization of the systemic inflammatory index on the baseline curve.
Point-of-Care Immunological Assays
Biomeme's platform offers immediate quantitative PCR tracking for cytokine and mucosal barrier expression. Assess anti-inflammatory pathway dynamics in under 15 minutes at the point of care, processed via CLIA-certified One Health Labs.
Curious how we measure this?
Learn about the foundational science of Transcriptomics and how Biomeme brings molecular profiling to the point of need.
Ready to Learn More?
Explore how Biomeme's capabilities are being deployed across the Wellness landscape.